Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases and cancer. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has over 65 employees. Since December 15th, 2023 Theradiag merged with Biosynex.
Looking for a particular Theradiag employee's phone or email?
Theradiag Questions
The Theradiag annual revenue was $6.26 million in 2026.
Bertrand de Castelnau is the CEO/MD of Theradiag.
3 people are employed at Theradiag.
The NAICS codes for Theradiag are [3254, 32, 32541, 325413, 325].
The SIC codes for Theradiag are [28, 283].
Top Theradiag Employees
